Literature DB >> 6894159

In vitro synthesis of human brain proteins including tubulin and actin by purified postmortem polysomes.

C A Marotta, B A Brown, P Strocchi, E D Bird, J M Gilbert.   

Abstract

Polysomes were prepared from human brain tissue 2-6 h postmortem; the polysomes were active in a cell-free protein synthesis system containing rabbit reticulocyte factors. Protein synthesis was totally dependent upon added MgCl2, ATP, the reticulocyte factor fraction, and the human polysome fraction. Human brain proteins synthesized in the presence of L-[35S]methionine were analyzed by one- and two-dimensional polyacrylamide gel electrophoresis. Over 250 proteins were synthesized and they extended in size up to 250,000 d; many of the most abundant native human brain proteins were synthesized, including tubulin and actin. It was shown that human brain alpha and beta tubulin and actin isomers synthesized in vitro from human postmortem polysomes have the same apparent molecular weights and isoelectric points as the corresponding proteins synthesized by rat polysomes from fresh cortices. The corresponding tubulin and actin synthesized by human and rat brain polysomes also yield the same radioactive methionine-containing peptides after digestion with Staphylococcus aureus V8 protease. These analyses indicate that postmortem polysomes contain active messenger RNA which can direct the partial and/or complete synthesis of actin and tubulin subunits and other human brain proteins.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6894159     DOI: 10.1111/j.1471-4159.1981.tb01688.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Detection of early gene expression changes during activation of human primary lymphocytes by in vitro synthesis of proteins from polysome-associated mRNAs.

Authors:  S Miyamoto; J Qin; B Safer
Journal:  Protein Sci       Date:  2001-02       Impact factor: 6.725

2.  A study on postmortem stability of vasopressin messenger RNA in rat brain compared with those in total RNA and ribosomal RNA.

Authors:  I Noguchi; H Arai; R Iizuka
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Aluminum, altered transcription, and the pathogenesis of Alzheimer's disease.

Authors:  D R Crapper McLachlan; W J Lukiw; T P Kruck
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

4.  Stability of messenger RNA in postmortem human brains and construction of human brain cDNA libraries.

Authors:  H Kobayashi; K Sakimura; R Kuwano; S Sato; F Ikuta; Y Takahashi; T Miyatake; S Tsuji
Journal:  J Mol Neurosci       Date:  1990       Impact factor: 3.444

5.  Characterisation of messenger RNA extracted post-mortem from the brains of schizophrenic, depressed and control subjects.

Authors:  C W Perrett; R M Marchbanks; S A Whatley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

6.  Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer disease brain: coding and noncoding regions of the fetal precursor mRNA are expressed in the cortex.

Authors:  S B Zain; M Salim; W G Chou; E M Sajdel-Sulkowska; R E Majocha; C A Marotta
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

7.  Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer disease.

Authors:  W S Griffin; C Ling; C L White; M Morrison-Bogorad
Journal:  Alzheimer Dis Assoc Disord       Date:  1990       Impact factor: 2.703

Review 8.  Tau-mediated dysregulation of RNA: Evidence for a common molecular mechanism of toxicity in frontotemporal dementia and other tauopathies.

Authors:  Shon A Koren; Sara Galvis-Escobar; Jose F Abisambra
Journal:  Neurobiol Dis       Date:  2020-05-12       Impact factor: 5.996

9.  Selective postmortem degradation of inducible heat shock protein 70 (hsp70) mRNAs in rat brain.

Authors:  S Pardue; A L Zimmerman; M Morrison-Bogorad
Journal:  Cell Mol Neurobiol       Date:  1994-08       Impact factor: 5.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.